| pubmed-article:7982493 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0020200 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C1171362 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0086376 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0470187 | lld:lifeskim |
| pubmed-article:7982493 | lifeskim:mentions | umls-concept:C0439792 | lld:lifeskim |
| pubmed-article:7982493 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7982493 | pubmed:dateCreated | 1995-1-3 | lld:pubmed |
| pubmed-article:7982493 | pubmed:abstractText | Sustained exposure of neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human beta 2-adrenoceptor (clone beta N22) to isoprenaline or iloprost (an agonist at the endogenously expressed IP prostanoid receptor) resulted in a substantial and selective down-regulation of the alpha subunit of the G-protein Gs. Treatment of these cells with the irreversible beta-adrenoceptor antagonist bromoacetyl alprenolol menthane diminished both the potency and the maximal ability of isoprenaline but not of iloprost to cause Gs alpha down-regulation. These results demonstrate that the extent of agonist-mediated Gs alpha down-regulation is dependent upon the availability of receptor to agonist. | lld:pubmed |
| pubmed-article:7982493 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7982493 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7982493 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7982493 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7982493 | pubmed:issn | 0014-5793 | lld:pubmed |
| pubmed-article:7982493 | pubmed:author | pubmed-author:MilliganGG | lld:pubmed |
| pubmed-article:7982493 | pubmed:author | pubmed-author:NiuJ TJT | lld:pubmed |
| pubmed-article:7982493 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7982493 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:7982493 | pubmed:volume | 355 | lld:pubmed |
| pubmed-article:7982493 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7982493 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7982493 | pubmed:pagination | 166-70 | lld:pubmed |
| pubmed-article:7982493 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:meshHeading | pubmed-meshheading:7982493-... | lld:pubmed |
| pubmed-article:7982493 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7982493 | pubmed:articleTitle | Receptor availability defines the extent of agonist-mediated G-protein down-regulation in neuroblastoma x glioma hybrid cells transfected to express the beta 2-adrenoceptor. | lld:pubmed |
| pubmed-article:7982493 | pubmed:affiliation | Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Scotland, UK. | lld:pubmed |
| pubmed-article:7982493 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7982493 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7982493 | lld:pubmed |
